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ABSTRACT
Cyclophosphamide (CPA) chemotherapy has been known to cause ovarian failure. 
CPA therapy leads to infertility via oxidative stress induced apoptosis of ovarian cells. 
Tocotrienols (T3), vitamin E isoform, is a much more potent antioxidant compared to 
tocopherols. T3 is a potent antioxidant and anti-inflammatory agent. The role of T3 in 
ovarian protection throughout chemotherapy remains un-elucidated, hence this study 
has been undertaken to investigate the role of T3 in the maintenance of normal female 
reproductive system from temporal infertility due to CPA administration. The 
alteration and regulation of ER and PR, genes and proteins, expression were 
investigated to ascertain the deleterious effect of CPA and whether co-administration 
with T3 showed any difference. That was hoped to explain the involvement of ER and 
PR signaling pathway as biomarker in maintaining fertility during chemotherapy 
treatment. 60 female ICR mice, aged between 8 to 10 weeks were divided into 5 
treatment groups: CPA, CPA&T3, normal saline, T3 only, and com oil only. The 
treatment was given for 30 consecutive days, followed by administration of pregnant 
mare serum gonadotrophin and human chorionic gonadotrophin to induce super 
ovulation. The mice were sacrificed at 14 to 16 hours post induction, after which all 
animal were euthanized. At dissection, both ovaries were removed, fixed in 10% 
formalin, processed and embedded in paraffin to form tissue blocks. Histological 
processing and Terminal deoxynucleotidyl transferase-mediated dUTP nick-end 
labeling (TUNEL) assays were performed on the tissue blocks. Both ovaries were 
dissected and immediately preserved in liquid nitrogen and then RNA extraction and 
cDNA synthesis were performed. Real-time quantitative PCR was performed using 
the syper green probe real time PCR. Concentration of the forward, reverse primers, 
probes, cDNA template, as well as the annealing temperature were optimized using 
real time PCR involvement caspase3, Bcl-2, ER, PR, GAPDH and b-actin genes. All 
IHC reactions included peroxidase for mouse Biotinylated primary antibody code 
(k3954) and horseradish peroxidase as secondary antibody. All data were subjected to 
statistical analysis by one-way ANOVA. The histological changes seen in the ovaries 
of CPA group include increase in degeneration of primary and secondary follicles, 
with a decrease in their total numbers; large follicles had incomplete and sometimes 
absent antrum. Whereas in CPA+T3 group, folliculogenesis was near normal, with 
regular antrum formation in large follicles and increased number of follicles in all 
stages. There was a significant reduction of TUNEL positive cells in the combined 
CPA&T3 group compared to CPA group by 11.23% (p<0.05). Our results established 
that combine CPA+T3 administration significantly up-regulated the gene expression 
of Bcl-2 (p<0.01) by 0.36 fold and caspace3 gene expression level was also 
significantly reduced (p<0 .0 1 ) and suppressed by 2 . 1 2  fold, compared to treatment 
with CPA alone. CPA+T3 also significantly reduced the expression of ER, PR genes 
and protein in the ovary of CPA-exposed mice (p<0.05). The results therefore 
indicated that co-administration of T3 with CPA confers protection against apoptosis 
and modulate altered genes and protein expression in ovaries. T3 is a potential 
candidate for ovarian preservation in chemotherapy-associated damage.
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CHAPTER ONE 
INTRODUCTION
1.1 RESEARCH BACKGROUND
Infertility has become a global problem affecting approximately 15% of both 
men and women of reproductive age. Anti-cancer therapy is one of the factors leading 
to decreased fertility (Poirot et al., 2002). According to the recent cancer statistics, the 
most common cancers diagnosed in women under the age of 40 are breast cancer, 
melanoma, cervical cancer, non-Hodgkin's lymphoma and leukemia (Jemal et al., 
2005). Current therapy of childhood cancer makes long-term survival a realistic 
outcome for most patients. The majority of young female cancer patients are expected 
to be cured and become long-term survivors (Jemal et al., 2011).
The improved long-term survival of adolescents and young women treated for 
cancer has resulted in increased focus on the effects of chemotherapy on ovarian 
function and its preservation. No established method for preservation of female 
fertility is currently available. Thus, investigation on ways to preserve fertility of 
women who had undergone such treatment is of utmost importance. In addition, 
increasing numbers of patients with autoimmune diseases, such as rheumatoid arthritis 
or systemic lupus erythematosus (Sonmezer and Oktay, 2004) are being treated 
successfully with chemotherapy.
Fertility management is recommended for women of fertile age undergoing 
chemotherapy, as the treatment has implications on family formation (Kirkman et al., 
2013). Chemotherapy leads to reduced fertility in women by inducing or hastening 
menopause (Hickey et al., 2009). In general, all chemotherapeutic drugs act by 
interrupting vital cell processes and arresting normal cell proliferation. The ovary is 
commonly affected by these drugs as it contained many rapidly dividing cells, 
especially those involved in oogenesis.
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